RNAi新药公司City Therapeutics登陆纳斯达克 扩容IPO募资约2亿美元
马萨诸塞州剑桥讯——临床阶段生物技术公司City Therapeutics（纳斯达克：CTY）10月15日晚宣布，其扩大规模的首次公开募股完成定价：以每股18.00美元发行11,111,111股普通股，募资总额预计约2.0亿美元（未扣除承销折扣、佣金和发行费用）。承销商获授30天期选择权，可额外购买最多1,666,666股普通股。
公司股票10月16日在纳斯达克全球市场开始交易，代码为CTY，发行预计于10月19日交割。高盛、Jefferies和Stifel担任本次发行的联席账簿管理人，Oppenheimer同为联席账簿管理人。
City Therapeutics致力于开发新一代RNA干扰（RNAi）疗法，是一家总部位于马萨诸塞州剑桥的临床阶段生物技术公司。此次发行规模较原计划有所扩大。
City Therapeutics Prices Upsized $200 Million IPO, Starts Trading on Nasdaq as CTY
CAMBRIDGE, Mass. — City Therapeutics, a clinical-stage biotechnology company developing next-generation RNA interference (RNAi) therapeutics, announced on the evening of October 15 the pricing of its upsized initial public offering: 11,111,111 shares of common stock at $18.00 per share, for expected gross proceeds of approximately $200.0 million before underwriting discounts, commissions and offering expenses. The underwriters were granted a 30-day option to purchase up to 1,666,666 additional shares.
The shares began trading on the Nasdaq Global Market on October 16 under the ticker CTY, and the offering is expected to close on October 19, 2026. Goldman Sachs, Jefferies and Stifel are joint book-running managers, with Oppenheimer also serving as a joint book-running manager.
City Therapeutics is headquartered in Cambridge, Massachusetts, and is developing next-generation RNAi therapeutics.
来源：GSM·美国（原文链接）
图片来源：City Therapeutics公司官方标志 / City Therapeutics official logo
GSM Global · 本篇英文版 English edition of this story
